| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | +11.0% | +202.2% |
| SG&A Expense | $25 | +38.9% | +31.6% |
| Operating Income | -$476 | +56.1% | +87.5% |
| Income Tax | $0 | — | — |
| Net Income | -$476 | +56.1% | +87.5% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $36K | +32.6% | +17.6% |
| Total Assets | $56K | +13.3% | -6.1% |
| Current Liabilities | $76K | +10.2% | +12.8% |
| Stockholders' Equity | -$20K | -2.4% | -158.1% |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $3K | — | — |
| Financing Cash Flow | $162 | — | — |
Business Overview
Naploy Corp., incorporated in Wyoming in April 2023, is a development-stage company focused on launching a health-related news blog and mobile application offering healthcare information, symptom diagnostics using AI technology, clinic search services, and advertising placement for medical institutions. The company generated service revenues of $13,129 for the nine months ended April 30, 2026 (compared to $4,372 in the prior year period), and is currently expanding from its initial Nigeria market toward other African countries while developing enhanced features including improved AI, map view, and booking services.
Segment Performance
The company operates as a single reportable segment. For the nine months ended April 30, 2026, total revenues were $13,129 compared to $4,372 in the prior year period (a 200% increase). For the three-month period ended April 30, 2026, revenues were $4,996 compared to $1,653 in the prior year period (a 202% increase). However, operating losses narrowed for the nine-month period to $8,784 compared to $17,302 in the prior year, primarily due to revenue growth offsetting consistent amortization expenses of $6,750.
Forward Guidance
"The ability of the Company to continue as a going concern is dependent upon the Company s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering." Management states that "the Company is attempting to commence operations and generate sufficient revenue" and that it "intends to raise additional funds by way of a private or public offering." No specific revenue targets, earnings guidance, or quantitative forward-looking metrics are provided.
Key Risk Factors
The company faces substantial doubt regarding its ability to continue as a going concern, with an accumulated deficit of $56,179 and net operating losses since inception; limited cash resources may be insufficient to support daily operations without additional funding through private or public offerings. The company is pre-revenue stage with no employees beyond officers and directors, relying entirely on advertising services for monetization. The company's AI-powered symptom diagnostic tool is for informational purposes only and does not provide medical advice, creating potential regulatory and liability risks if users rely on it for medical decisions. The company's deferred revenue of $15,321 indicates customer commitments that must be fulfilled, and failure to deliver services could impact future customer acquisition and reputation.
| — |